Pharmacological and genomic profiling identifies NF-[kappa]B-targeted treatment strategies for mantle cell lymphoma

A screen for compounds that may inhibit the growth of hematological malignancies reveals the specific dependence of some mantle cell lymphoma (MCL) cell lines on canonical or alternative NF-[kappa]B signaling. As also seen in patients, genetic alterations affecting alternative NF-[kappa]B signaling confer insensibility to ibrutinib, a compound that was recently approved for MCL treatment. This alternative signaling pathway underscores the need to tailor treatments to the specific driving pathways in each patient group.